Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Operating Income: 2010-2025

Historic Operating Income for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $66.3 million.

  • Catalyst Pharmaceuticals' Operating Income rose 30.17% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.8 million, marking a year-over-year increase of 48.74%. This contributed to the annual value of $195.1 million for FY2024, which is 124.77% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Operating Income is $66.3 million, which was down 0.05% from $66.3 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Operating Income ranged from a high of $66.3 million in Q2 2025 and a low of -$37.2 million during Q3 2023.
  • In the last 3 years, Catalyst Pharmaceuticals' Operating Income had a median value of $50.9 million in 2024 and averaged $43.4 million.
  • In the last 5 years, Catalyst Pharmaceuticals' Operating Income plummeted by 248.15% in 2023 and then soared by 236.90% in 2024.
  • Catalyst Pharmaceuticals' Operating Income (Quarterly) stood at $12.7 million in 2021, then soared by 141.73% to $30.8 million in 2022, then skyrocketed by 35.36% to $41.7 million in 2023, then surged by 50.73% to $62.8 million in 2024, then skyrocketed by 30.17% to $66.3 million in 2025.
  • Its Operating Income was $66.3 million in Q3 2025, compared to $66.3 million in Q2 2025 and $63.4 million in Q1 2025.